This study will investigate the efficacy of Degarelix, a Luteinizing Hormone Releasing
Hormone (LHRH) antagonist, to reduce prostate volume prior to permanent seed prostate
brachytherapy. There are 2 eligible populations of men, all of whom will have selected
brachytherapy as their treatment of choice for their prostate cancer. Either they have an
enlarged prostate that requires size reduction to render brachytherapy technically feasible,
or they require androgen ablation in conjunction with brachytherapy for optimal tumor
control. The hypothesis is that Degarelix will provide > 30% volume reduction by 3 months in
> 30% of men.